Literature DB >> 2517209

Combined immunodeficiency with defective expression in MHC class II genes.

C Griscelli1, B Lisowska-Grospierre, B Mach.   

Abstract

MHC class II deficiency is an inherited immunodeficiency disease characterized by the presence of a normal number of T and B lymphocytes and profound anomaly of cellular and humoral responses to foreign antigens. All bone-marrow-derived cells (including B lymphocytes, monocytes and activated T lymphocytes) and also enterocytes and endothelial cells do not express all HLA class II (DR, DQ and DP) molecules on their membrane. It is known that the proper recognition of foreign antigens depends on their presentation, together with HLA class II molecules, on the membrane of antigen-presenting cells. MHC class II deficient combined immunodeficiency confirms the important role of MHC gene products in immune-defence mechanisms. Patients suffer from repeated and severe infections that are frequently the cause of death. The defect in HLA class II expression is the consequence of a lack of synthesis of HLA class II alpha and beta chains in patients' cells. Studies performed at DNA and RNA levels showed that there was no gross abnormality of MHC class II genes and that mRNA for all HLA molecules was not detected in patients' cells. These results, together with segregation studies performed in several families, suggested that the defect in HLA class II gene expression involves a transacting regulatory factor. Direct transcription assays showed that the disease is characterized by an absence of HLA class II gene transcription. An analysis of the specific binding of nuclear proteins from patients' cell lines to HLA class II promotor showed that a specific protein, RF-X, which normally binds to a regulatory sequence common to HLA class II promotors, is affected in MHC class II combined immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517209

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN: 0893-5300


  30 in total

Review 1.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

Review 2.  The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes.

Authors:  A DeSandro; U M Nagarajan; J M Boss
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

3.  Self-association of CIITA and its transactivation potential.

Authors:  T J Sisk; S Roys; C H Chang
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

4.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 6.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters.

Authors:  C Herrero Sanchez; W Reith; P Silacci; B Mach
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

8.  Regulatory factor-X binding to mutant HLA-DRA promoter sequences.

Authors:  S L Hasegawa; J H Sloan; W Reith; B Mach; J M Boss
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

9.  Interferon-γ resets muscle cell fate by stimulating the sequential recruitment of JARID2 and PRC2 to promoters to repress myogenesis.

Authors:  Priya Londhe; Judith K Davie
Journal:  Sci Signal       Date:  2013-12-10       Impact factor: 8.192

10.  The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.

Authors:  J A Brown; E M Rogers; J M Boss
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.